|
Cinfa celebrates its 10 years of presence in Kuwait with
a strong commitment to
health and well-being
(Kuwait) - The European pharmaceutical laboratory,
Cinfa, recently
held a gala dinner to
celebrate its 10 years of
presence in Kuwait. The
celebration took place on
February 8th at the renowned
The Regency Hotel with the
aim of recognizing and
highlighting the arrival of
Cinfa to the Kuwaiti
population a decade ago.
It’s commitment during all
these years has been to
offer a better and healthier
life through access to
affordable medicines with
the highest quality, safety,
and effectiveness.
Cinfa representatives in the
region welcomed
personalities from the
Spanish Embassy in Kuwait,
as well as doctors and
pharmacists from the Kuwaiti
Ministry of Health. More
than 250 healthcare
professionals also attended
the gala, in addition to
Al-Hajery & Sons and Ali
Abdulwahab Al Mutawa
Commercial (AAW), who play
an essential role in its
mission to improve people’s
quality of life. In
addition, the gala dinner
had several representatives
from Cinfa’s esteemed
PharmaAccess regional
partners.
Driven by life:
Celebration, Commitment, and
Reflection
Cinfa has worked tirelessly
to provide innovative and
affordable healthcare
solutions, collaborating
closely with healthcare
professionals to understand
and address their real
needs.
During the gala dinner,
Franc Vives, Cinfa’s Chief International Officer,
has highlighted that “we
have two main challenges:
continue increasing market
penetration and market share
to bring our health
solutions to more patients,
and increase presence in the
institutional sector”.
From its side,
Julio Maset, Cinfa’s Corporate Scientific Director,
has explained that “Cinfa is
continuously expanding its
portfolio in different
health areas, but in the
Gulf and specially in
Kuwait, Cinfa is mainly
focusing in cardiovascular
and respiratory diseases, as
well as pain control and
antibiotics”.
And has added that “in
cardiovascular, one of the
main success key factors is
patient compliance - to
ensure that the patient will
follow the medication as it
has been subscribed. In pain
and inflammation control,
COX-2 inhibitors are one of
our major overtaking, the
efficacy is the same in
comparison with other
non-steroidal drugs, but the
tolerance and safety is much
better.”
Julio Maset concluded saying
that “In the near future
Cinfa plans to launch drugs
in metabolic syndrome and
diabetes control”.
Ongoing Commitment:
Working For and With the
Patient
Through that celebration,
Cinfa recalled and shared a
common goal: working for and
with the patient. In this
sense, the company maintains
its commitment to expanding
medication coverage and
addressing present and
future health challenges,
such as the increasing
longevity and prevalence of
chronic conditions.
The celebration of the 10th
anniversary not only has
signified a milestone in
Cinfa's history in Kuwait,
but also has reflected its
determination to continue
contributing to the
well-being of all.
PRINT
THIS ARTICLE
|